title: Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy.
abstract: The objective of this study is to evaluate the effects of solifenacin on double-J stent-related symptoms following uncomplicated ureterosocpic lithotripsy (URSL). A total of 70 patients who underwent double-J ureteral stent insertion following URSL were consecutively recruited and received solifenacin postoperatively. Another 70 age- and sex-matched subjects without solifenacin therapy were enrolled as a control group. The clinical data including stone and stent characteristics were collected. All subjects completed the brief-form Ureteral Symptom Score Questionnaire (Chinese-version) to assess the lower urinary tract symptoms, stent-related body pain and hematuria 2 weeks after operation. The severity of stent-related symptoms was compared between two groups. The mean age was 53.8 in solifenacin group and 53.4 years in the control group (p = 0.87). The stone characteristics, stent size, position and curl completeness were similar in both groups. Compared to the control group, solifenacin group had significantly lower total symptom score, urgency and urge incontinence scores. As for stent-related body pain, solifenacin group had significantly less flank, abdominal, urethral pain and hematuria scores (all p < 0.05). The solifenacin versus control group showed significant benefits in lower urinary tract symptoms, stent-related pain and hematuria in both genders (all p < 0.05). Four subjects encountered minor adverse events (5.7 %) and one had urinary retention (1.4 %) in solifenacin group. For patients undergoing URSL and double-J stent indwelling, postoperative solifenacin use was effective and well-tolerated for the treatment of lower urinary tract symptoms, stent-related body pain and hematuria irrespective of genders.
authors.affiliation: Department of Urology, National Taiwan University Hospital, and National Taiwan University College of Medicine, Taipei, Taiwan.
authors.forename: Yuan-Ju
authors.initials: YJ
authors.lastname: Lee
authors.forename: Kuo-How
authors.initials: KH
authors.lastname: Huang
authors.forename: Hung-Ju
authors.initials: HJ
authors.lastname: Yang
authors.forename: Hong-Chiang
authors.initials: HC
authors.lastname: Chang
authors.forename: Jun
authors.initials: J
authors.lastname: Chen
authors.forename: Teng-Kai
authors.initials: TK
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006417:Hematuria / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008096:Lithotripsy / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D011446:Prospective Studies; D011812:Quinuclidines / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D015607:Stents / Q000009:adverse effects*; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D014514:Ureteral Calculi / Q000628:therapy*; D014517:Ureteral Obstruction / Q000517:prevention & control; D018666:Ureteroscopy / Q000009:adverse effects; D064804:Urological Agents / Q000627:therapeutic use
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D064804:Urological Agents; D000069464:Solifenacin Succinate